Investigating patients’ reports on the quality and consistency of melanoma follow-up care in Australia would assist in evaluating if this care is effective and meeting patients’ needs. The objective of this study was to obtain and explore the patients’ account of the technical and interpersonal aspects of melanoma follow-up care received. An online survey was conducted to acquire details of patients’ experience. Participants were patients treated in Australia for primary melanoma. Qualitative and quantitative data about patient perceptions of the nature and quality of their follow-up care were collected, including provision of melanoma specific information, psychosocial support, and imaging tests received. Inconsistencies were reported in the provision and quality of care received. Patient satisfaction was generally low and provision of reassurance from health professionals was construed as an essential element of quality of care. “Gaps” in follow-up care for melanoma patients were identified, particularly provision of adequate psychosocial support and patient education. Focus on strategies for greater consistency in the provision of support, information, and investigations received, may generate a cost dividend which could be reinvested in preventive and supportive care and benefit patient well-being. 1. Introduction Globally, Australia has the highest incidence of melanoma, with annual rates continuing to rise [1]. Individuals with a primary melanoma have 8–12% risk of developing a second primary melanoma and an increased risk of developing a nonmelanoma skin cancer [2–5], and therefore posttreatment monitoring for recurrence and new primary melanomas is important. The purpose of follow-up is to detect recurrence and/or progression at an early treatable stage, identify treatment-related morbidity (e.g., lymphoedema), identify new melanoma or nonmelanoma skin cancers, and provide reassurance and education [6]. Good practice in follow-up includes effective coordination of care, consistency in care provision [7, 8], evidence-based testing, and psychosocial support [6–9]. Patient perceptions can provide valuable insight into the quality of melanoma follow-up care and identify potential areas for improvement. Quality of patient care can be defined in both technical and interpersonal terms [10]. Here, “technical” refers to best practice based on current evidence coupled with care providers’ knowledge, judgment, and skill in implementation [10]. The 2008 Australian Cancer Network Melanoma Guidelines publication describes best practice guidelines for melanoma
References
[1]
“Cancer. Cat. no . CAN 38; Cancer series no.42,” Australian Institute of Health and Welfare, 2012, http://www.aihw.gov.au/cancer/.
[2]
A. Uliasz and M. Lebwohl, “Patient education and regular surveillance results in earlier diagnosis of second primary melanoma,” International Journal of Dermatology, vol. 46, no. 6, pp. 575–577, 2007.
[3]
L. Titus-Ernstoff, A. E. Perry, S. K. Spencer et al., “Multiple primary melanoma: two-year results from a population-based study,” Archives of Dermatology, vol. 142, no. 4, pp. 433–438, 2006.
[4]
P. T. Bradford, D. M. Freedman, A. M. Goldstein, and M. A. Tucker, “Increased risk of second primary cancers after a diagnosis of melanoma,” Archives of Dermatology, vol. 146, no. 3, pp. 265–272, 2010.
[5]
G. B. Yang, J. S. Barnholtz-Sloan, Y. Chen, and J. S. Bordeaux, “Risk and survival of cutaneous melanoma diagnosed subsequent to a previous cancer,” Archives of Dermatology, vol. 147, no. 12, pp. 1395–1402, 2011.
[6]
Clinical Practice Guidelines for the Management of Melanoma in Australia and New Zealand, Australian Cancer Network Melanoma Guidelines Revision Working Party, 2008, http://www.nhmrc.gov.au/_files_nhmrc/publications/attachments/cp111.pdf.
[7]
C. Holterhues, L. V. van de Poll-Franse, E. de Vries, H. A. M. Neumann, and T. E. C. Nijsten, “Melanoma patients receive more follow-up care than current guideline recommendations: a study of 546 patients from the general Dutch population,” Journal of the European Academy of Dermatology and Venereology, vol. 26, no. 11, pp. 1389–1395, 2012.
[8]
U. Leiter, A. A. Marghoob, K. Lasithiotakis et al., “Costs of the detection of metastases and follow-up examinations in cutaneous melanoma,” Melanoma Research, vol. 19, no. 1, pp. 50–57, 2009.
[9]
R. L. Morton, L. Rychetnik, K. McCaffery, J. F. Thompson, and L. Irwig, “Patients' perspectives of long-term follow-up for localised cutaneous melanoma,” European Journal of Surgical Oncology, vol. 39, no. 3, pp. 297–303, 2013.
[10]
A. Donabedian, “The quality of care. How can it be assessed?” Journal of the American Medical Association, vol. 260, no. 12, pp. 1743–1748, 1988.
[11]
P. D. Cleary and B. J. McNeil, “Patient satisfaction as an indicator of quality care,” Inquiry, vol. 25, no. 1, pp. 25–36, 1988.
[12]
G. C. Pascoe, “Patient satisfaction in primary health care: a literature review and analysis,” Evaluation and Program Planning, vol. 6, no. 3-4, pp. 185–210, 1983.
[13]
L. Rychetnik, K. McCaffery, R. Morton, and L. Irwig, “Psychosocial aspects of post-treatment follow-up for stage I/II melanoma: a systematic review of the literature,” Psycho-Oncology, vol. 22, no. 4, pp. 721–736, 2013.
[14]
D. Carter, H. H. A. Afzali, J. Street, T. Bessen, and S. Neuhaus, “Melanoma follow up: time to generate the evidence,” Australian Health Review, vol. 37, no. 4, pp. 501–503, 2013.
[15]
C. C. Gotay and I. S. Pagano, “Assessment of Survivor Concerns (ASC): a newly proposed brief questionnaire,” Health and Quality of Life Outcomes, vol. 5, article 15, 2007.
[16]
QSR International Pty, NVivo Qualitative Analysis Software. Version 9, [computer program], QSR International Pty, 2010.
[17]
V. Braun and V. Clarke, “Using thematic analysis in psychology,” Qualitative Research in Psychology, vol. 3, no. 2, pp. 77–101, 2006.
[18]
N. K. Choudhry, R. H. Fletcher, and S. B. Soumerai, “Systematic review: the relationship between clinical experience and quality of health care,” Annals of Internal Medicine, vol. 142, no. 4, pp. 260–273, 2005.
[19]
A. L. Dancey, B. S. Mahon, and S. S. Rayatt, “A review of diagnostic imaging in melanoma,” Journal of Plastic, Reconstructive and Aesthetic Surgery, vol. 61, no. 11, pp. 1275–1283, 2008.
[20]
M. W. Ludgate, M. S. Sabel, D. R. Fullen et al., “Internet use and anxiety in people with melanoma and nonmelanoma skin cancer,” Dermatologic Surgery, vol. 37, no. 9, pp. 1252–1259, 2011.
[21]
P. N. Butow, M. Maclean, S. M. Dunn, M. H. N. Tattersall, and M. J. Boyer, “The dynamics of change: cancer patients' preferences for information, involvement and support,” Annals of Oncology, vol. 8, no. 9, pp. 857–863, 1997.
[22]
G. M. Leydon, M. Boulton, C. Moynihan et al., “Cancer patients' information needs and information seeking behaviour: in depth interview study,” British Medical Journal, vol. 320, no. 7239, pp. 909–913, 2000.
[23]
L. J. Loescher, J. D. Crist, and L. A. C. L. Siaki, “Perceived intrafamily melanoma risk communication,” Cancer Nursing, vol. 32, no. 3, pp. 203–210, 2009.
[24]
L. J. Loescher, J. D. Crist, L. Cranmer, C. Curiel-Lewandrowski, and J. A. Warneke, “Melanoma high-risk families' perceived health care provider risk communication,” Journal of Cancer Education, vol. 24, no. 4, pp. 301–307, 2009.
[25]
S. A. Oliveria, J. L. Hay, A. C. Geller, M. K. Heneghan, M. S. McCabe, and A. C. Halpern, “Melanoma survivorship: research opportunities,” Journal of Cancer Survivorship, vol. 1, no. 1, pp. 87–97, 2007.
[26]
P. Yates, “Cancer care coordinators: realising the potential for improving the patient journey,” Cancer Forum, vol. 28, no. 3, pp. 128–132, 2004.
